CareDx (NASDAQ: CDNA), a leading transplant diagnostics company, saw its shares surge 7.92% in pre-market trading on Tuesday following the release of its third-quarter financial results that significantly exceeded analyst expectations. The company reported strong earnings growth and raised its full-year guidance, boosting investor confidence in its future prospects.
For the quarter ended September 30, CareDx reported adjusted earnings per share of $0.28, doubling the analyst consensus estimate of $0.14 and marking a 100% increase from the same period last year. Revenue for the quarter came in at $100.1 million, surpassing the analyst forecast of $95.25 million and representing a 20.72% year-over-year growth. The company's testing services revenue, a key driver of its performance, increased by 19% to reach $72.2 million, with testing volume growing 13% to 50,300 tests processed during the quarter.
Following the strong quarterly performance, CareDx raised its full-year 2025 revenue guidance to a range of $372 million to $376 million. The company also increased its adjusted EBITDA forecast to between $35 million and $39 million. These upward revisions in guidance, coupled with the introduction of new products like AlloSeq Tx11 and HistoMap Kidney, underscore CareDx's continued innovation and growth in the transplant care market. The market's positive reaction to the earnings beat and improved outlook reflects growing investor confidence in CareDx's ability to maintain its momentum and deliver substantial growth in both profitability and top-line expansion.
Comments